Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Investing Activities (2019 - 2025)

Legend Biotech filings provide 7 years of Cash from Investing Activities readings, the most recent being $638.5 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 826.39% to $638.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $709.6 million, a 183.42% increase, with the full-year FY2025 number at $709.6 million, up 183.42% from a year prior.
  • Cash from Investing Activities hit $638.5 million in Q4 2025 for Legend Biotech, up from -$20.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $638.5 million in Q4 2025 to a low of -$695.6 million in Q2 2024.
  • Median Cash from Investing Activities over the past 5 years was -$83.1 million (2022), compared with a mean of -$35.8 million.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 4807.27% in 2023 and later soared 826.39% in 2025.
  • Legend Biotech's Cash from Investing Activities stood at -$195.0 million in 2021, then soared by 59.82% to -$78.3 million in 2022, then surged by 620.15% to $407.5 million in 2023, then tumbled by 121.57% to -$87.9 million in 2024, then soared by 826.39% to $638.5 million in 2025.
  • The last three reported values for Cash from Investing Activities were $638.5 million (Q4 2025), -$20.0 million (Q3 2025), and -$165.5 million (Q2 2025) per Business Quant data.